Uncategorized
Positive topline results announced for phase 3 trial of Seciera for dry eye
Seciera for the treatment of dry eye disease has met primary and key secondary endpoints in a phase 3 confirmatory clinical trial, according to a Sun Pharma press release.The 12-week, multicenter, randomized, double-masked, vehicle-controlled trial included 744 dry eye patients who were treated with Seciera (cyclosporine A 0.09% ophthalmic solution) or its vehicle.